CA-WASTEFUEL
10.3.2022 11:17:11 CET | Business Wire | Press release
WasteFuel and Maersk have today announced a commercial-scale bio-methanol partnership, which is set to help accelerate the decarbonisation of the shipping sector.
Maersk intends to buy 30,000 tons per year of WasteFuel bio-methanol, an order to help fulfil the demand of its 12 new green methanol powered ships planned to be operational by 2024.
Initially this green methanol will be made from the conversion of municipal waste in South America by 2024, but both partners expect expanding projects and production of green methanol further.
This announcement builds upon Maersk Growth’s investment in WasteFuel last year, under Its decarbonisation theme, as part of Maersk's strategy to reach net zero by 2040.
This partnership has significant implications for some of the largest consumer product businesses in the world, with green fuel set to reduce the emissions footprint of the products bought and shipped globally.
Speaking from Copenhagen, Denmark, Henriette Hallberg Thygesen, CEO of Fleet & Strategic Brands, A.P. Moller – Maersk said, “To drive the massive scale-up of green fuels we need to transition towards decarbonisation, production must increase in time. Green methanol is the only market-ready sustainable fuel available today for shipping and production must be accelerated through collaboration across the ecosystem and around the world. That is why these partnerships mark an important milestone to get the transition to green energy underway.”
Speaking from WasteFuel’s headquarters in Los Angeles, California, Trevor Neilson, Co-founder, Chairman and CEO said, "Last year, many of the world’s largest companies including Amazon, Ikea, Apple, Nestle and Patagonia pledged to reach net-zero emissions by 2050. Ships transport nearly as much as 90% of globally traded goods by volume and produce nearly 1.1 billion tons of carbon dioxide emissions, which rivals the annual output of Germany, the world’s sixth-largest emitter. Without green fuel solutions, corporate net-zero commitments will be impossible to meet."
Compared to conventional fuels, WasteFuel aims for its marine fuels to reduce CO2 emissions by 95%, to cut Nitrogen Oxide emissions by up to 80%, and to eliminate sulphur oxide and particulate matter emissions.
Maersk Growth, the Corporate Venture arm of A.P. Moller – Maersk announced their investment in WasteFuel in September 2021. With their investment, Morten Bo Christiansen, VP and Head of Decarbonisation at A.P. Moller – Maersk joined Trevor Neilson, Guillaume Lucci, Par Lindstrom, Bradley Ferrell, and Guy Oseary on WasteFuel’s Board of Directors.
WasteFuel, using proven technologies to convert waste - which would otherwise decompose releasing greenhouse gasses - into low carbon fuels, is driving solutions to decarbonise air, land, and sea transport. In addition to the green methanol project with Maersk, the company has several biorefinery projects underway including a project in the Philippines to produce Sustainable Aviation Fuel and bio-methanol in partnership with Prime Infra and NetJets and projects across the Americas and Asia to produce Renewable Natural Gas and green methanol.
About WasteFuel
WasteFuel uses proven technologies to address the climate emergency and revolutionise mobility. We convert municipal (trash) and agricultural waste into low-carbon fuels, renewable natural gas, and green methanol.
WasteFuel investors include Maersk, Marc Benioff’s TIME Ventures, i(x) Net Zero, NetJets, Prime Infra, Guy Oseary, and Aileen Getty.
For more information visit: www.wastefuel.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220310005116/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 08:36:00 CEST | Press release
Discovered by Takeda in Japan, ORZEYFUL has the Potential to Redefine Care Beyond Individual Symptom Management for Adults Living with Narcolepsy Type 1 (NT1) Landmark Phase 3 Studies Demonstrated Significant and Meaningful Improvements Across the Full Range of NT1 Symptoms Evaluated in Clinical Trials Compared to Placebo Milestone Marks Third Major Regulatory Approval Secured for ORZEYFUL Around the World Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly
Fasset Hits $1B Valuation as SBI Group Leads $68M Series C to Scale AI-Powered Stablecoin Neobanking24.8.2026 08:03:00 CEST | Press release
Round led by SBI Group follows $51 million Series B raise in May 2026, marking ascent as one of the fastest-growing neobanking platforms. Capital will expand Own Network and deepen AI across stablecoin settlement, tokenization, and corridor banking. Fasset now processes more than $40 billion in annualized transaction volume, serving 3 million+ wallets and more than 1,000 enterprises across 125 countries. Fasset, the AI-powered stablecoin neobanking platform, today announced it has raised $68 million in Series C funding at a $1 billion valuation. The financing was led by SBI Group and follows Fasset’s $51 million Series B earlier this year, which brought Speedinvest onto the cap table alongside a group of strategic investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823503947/en/ Mohammad Raafi Hossain, Co-Founder and CEO, Fasset The new capital will support the expansion of Own Network, Fasset’s regulated financial
Zanders Expands DACH Region with New Office in Vienna, Austria24.8.2026 07:11:00 CEST | Press release
Zanders, the global treasury, risk, and technology consultancy, today announced a significant expansion of its DACH region with the opening of a new office in Vienna. The move builds on Zanders' continued growth across Germany, Austria, and Switzerland, and marks another step in the firm's strategy of deepening its presence in the markets where client demand for specialized treasury, risk, and corporate finance advisory is growing fastest. DACH has been one of Zanders' priority regions for several years, with the firm steadily expanding its team and client base across Germany and Switzerland. Austria represents a natural next step in that growth: in conversations with clients in the market, Zanders has seen growing interest in treasury transformation and financing support, as companies work through interest rate volatility, refinancing needs, and a broader shift toward more digitized, centralized treasury operations. The new Vienna office allows Zanders to be closer to clients' operati
Novotech Strengthens Presence in Japan with Opening of Tokyo Office24.8.2026 01:01:00 CEST | Press release
Novotech, a leading global biotech CRO and full-service clinical research organization, has strengthened its established presence in Japan with the opening of a new office in Tokyo. The investment builds on Novotech’s existing operations and clinical trial activity in Japan and further enhances its ability to support Japanese biopharma companies as they advance programs regionally and across key international markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823592174/en/ Takeshi Mori, Novotech Country Head, Japan The Tokyo office will serve as a strategic hub for Novotech’s growing operations in Japan, providing enhanced local expertise and strengthening collaboration with clients, partners, research institutions, and innovation ecosystems across the region. Novotech is currently supporting ongoing studies in Japan and provides sponsors with integrated support across early-phase clinical development in Australia, F
FDA Authorizes ZYN ULTRA Nicotine Pouches Following Scientific Review21.8.2026 21:11:00 CEST | Press release
Authorizations add selection of ZYN ULTRA products to PMI U.S.’s growing portfolio of better alternatives for legal-age adults who smoke or use traditional oral tobacco products Philip Morris International Inc. (NYSE: PM) today announces that the U.S. Food and Drug Administration (FDA) issued Marketing Granted Orders to PMI’s U.S. affiliate, Swedish Match USA, Inc., authorizing the marketing of 11 ZYN ULTRA moist oral nicotine pouch products, including all 9mg variants and one 11mg variant. Additional 11mg variants remain under scientific review. Today’s action further enhances PMI’s leadership role in the smoke-free category. “We are delighted with the FDA’s decision to authorize a range of ZYN ULTRA products, which will build on ZYN’s position as America’s leading smoke-free product brand,” said Stacey Kennedy, PMI U.S. CEO. “We look forward to expanding our portfolio of better choices for the 45 million Americans who consume nicotine products.” ZYN ULTRA positions the brand to furth
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom